215 related articles for article (PubMed ID: 2505919)
1. Combination chemotherapy of advanced breast cancer. Comparison of dibromodulcitol, doxorubicin, vincristine, and fluoxymesterone to thiotepa, doxorubicin, vinblastine, and fluoxymesterone: an Eastern Cooperative Oncology Group Study.
Skeel RT; Andersen JW; Tormey DC; Benson AB; Asbury RF; Falkson G
Cancer; 1989 Oct; 64(7):1393-9. PubMed ID: 2505919
[TBL] [Abstract][Full Text] [Related]
2. Induction chemotherapy of dibromodulcitol, Adriamycin, vincristine, tamoxifen, and Halotestin with methotrexate in metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1181).
Chang AY; Putt M; Pandya KJ; Harris J; Gelman R; Tormey DC; Falkson G
Am J Clin Oncol; 1998 Feb; 21(1):99-104. PubMed ID: 9499270
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
[TBL] [Abstract][Full Text] [Related]
4. Vinblastine, adriamycin, thiotepa, and halotestin (VATH): therapy for advanced breast cancer refractory to prior chemotherapy.
Perloff M; Hart RD; Holland JF
Cancer; 1978 Dec; 42(6):2534-7. PubMed ID: 103610
[TBL] [Abstract][Full Text] [Related]
5. One-day VATH (vinblastine, Adriamycin, thiotepa, and Halotestin) therapy for advanced breast cancer refractory to chemotherapy.
Hart RD; Perloff M; Holland JF
Cancer; 1981 Oct; 48(7):1522-7. PubMed ID: 6793224
[TBL] [Abstract][Full Text] [Related]
6. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
[TBL] [Abstract][Full Text] [Related]
7. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.
Perloff M; Norton L; Korzun AH; Wood WC; Carey RW; Gottlieb A; Aust JC; Bank A; Silver RT; Saleh F; Canellos GP; Perry MC; Weiss RB; Holland JF
J Clin Oncol; 1996 May; 14(5):1589-98. PubMed ID: 8622076
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer.
Ransom DT; Neuberg D; Loprinzi CL; Tormey DC; Blum RH; Harris JE; Asbury RF; Falkson G
Am J Clin Oncol; 1991 Feb; 14(1):45-8. PubMed ID: 1898999
[TBL] [Abstract][Full Text] [Related]
9. Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: an Eastern Cooperative Oncology Group study.
Falkson G; Gelman R; Glick J; Falkson CI; Harris J
J Clin Oncol; 1994 Jan; 12(1):45-9. PubMed ID: 8270982
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer.
Loprinzi CL; Tormey DC; Rasmussen P; Falkson G; Davis TE; Falkson HC; Chang AY
J Clin Oncol; 1986 Jan; 4(1):46-56. PubMed ID: 3510282
[TBL] [Abstract][Full Text] [Related]
11. Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials.
Tormey DC; Gray R; Falkson HC; Gilchrist K; Abeloff MD; Falkson G
Recent Results Cancer Res; 1993; 127():185-96. PubMed ID: 8502815
[No Abstract] [Full Text] [Related]
12. Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trial.
Lichtman SM; Budman D; Bosworth H; Allen S; Schulman P; Weiselberg L; Weiss R; Lehrman D; Vinciguerra V
Am J Clin Oncol; 1991 Aug; 14(4):317-21. PubMed ID: 1907428
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP).
DiStefano A; Yap HY; Blumenschein GR
Cancer Treat Rep; 1981; 65(1-2):33-8. PubMed ID: 7013977
[TBL] [Abstract][Full Text] [Related]
14. VP-16 and adriamycin in patients with advanced breast cancer.
Vaughn CB; Maniscalco-Greb E; Lockhard C; Groshko G; Enochs K; Duffin H; Demitrish M
Am J Clin Oncol; 1982 Oct; 5(5):505-9. PubMed ID: 6897491
[TBL] [Abstract][Full Text] [Related]
15. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.
Falkson G; Gelman R; Falkson CI; Glick J; Harris J
J Clin Oncol; 1991 Dec; 9(12):2153-61. PubMed ID: 1960558
[TBL] [Abstract][Full Text] [Related]
16. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
[TBL] [Abstract][Full Text] [Related]
17. Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment. An Eastern Cooperative Oncology Group study.
Falkson G; Gelman RS; Glick J; Falkson CI; Harris J
Ann Oncol; 1992 Nov; 3(9):768-70. PubMed ID: 1450067
[No Abstract] [Full Text] [Related]
18. Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study.
Hoogstraten B; George SL; Samal B; Rivkin SE; Costanzi JJ; Bonnet JD; Thigpen T; Braine H
Cancer; 1976 Jul; 38(1):13-20. PubMed ID: 947510
[TBL] [Abstract][Full Text] [Related]
19. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
20. Short term high density systemic therapy for metastatic breast cancer.
Tormey DC; Kline JC; Palta M; Davis TE; Love RR; Carbone PP
Breast Cancer Res Treat; 1985; 5(2):177-88. PubMed ID: 2410072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
